Safety findings

Case reportAbstract inspected

A published case describes ischemic priapism after reported melanotan II injection that required surgical treatment. This supports a reported serious event, not an estimate of its frequency or proof that every associated condition is caused by melanotan II.^[1]

Product identity and individual factors limit causal inference from a single report.
The report's authors state this was only the third melanotan-II-associated priapism case reported in the literature at the time of publication (2021), consistent with a rare but possibly underreported event.

Inspection history

Clinical review: not reviewed by a qualified clinician.

2026-09-08 · Independently inspected the listed passages; replaced or qualified inherited assertions. No qualified clinical review has occurred.

2026-09-09 · Freshly reread the abstract via NCBI E-utilities; added the authors' own statement about prior case counts, and identified two further case reports and an FDA safety row as separate additions rather than altering this claim's scope. No qualified clinical review.

Regulatory recordSupporting passage inspected

FDA's bulk drug substance safety review lists Melanotan II as a withdrawn compounding nomination, citing published case reports of serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism, in addition to a general immunogenicity/aggregation concern.^[2]

This is FDA's own regulatory summary of published case reports, not this batch's independent inspection of the underlying melanoma/PRES/toxidrome case reports themselves.
Case reports describe individual events and do not establish an incidence rate or exclude other causes.

Inspection history

Clinical review: not reviewed by a qualified clinician.

2026-09-09 · New source relationship identified and added in the peptide-misc batch on 2026-09-09 while rereading the FDA bulk-safety page; proposed addition awaits independent editorial review.

Case reportAbstract inspected

Separate published case reports describe reversible oral and gingival pigmentation after prolonged self-injection of melanotan II, and a possible case of renal infarction attributed to melanotan II use. These are individual case reports, not an established rate of harm, and do not exclude other causes.^[3][4]

Single case reports cannot determine incidence or exclude other contributors.
Only the indexed abstracts were inspected; full case photographs, imaging and clinical-course detail were not reviewed.

Inspection history

Clinical review: not reviewed by a qualified clinician.

2026-09-09 · New sources identified and added in the peptide-misc batch on 2026-09-09 via a targeted PubMed search for melanotan II adverse-event case reports; proposed addition awaits independent editorial review.

What remains unresolved

Editorial assessment

These notes describe the scope of this review. Linked PMIDs are audit identifiers; an identifier alone does not verify a claim.

Retained a directly inspected priapism case report without a numerical risk estimate.

Cancer causality/incidence, kinetics and safety of uncontrolled products remain unresolved.
Other inherited assertions not supported by the published claim set remain unverified; no qualified clinician review has occurred.

This reference does not supply a dosing plan, monitoring timetable or recovery regimen. Discuss personal symptoms, medicines and laboratory results with a qualified clinician.

Explore the interaction evidence for this compound →

References

Melanotan Tanning Injection: A Rare Cause of Priapism.
2021-01-15. PMID:33460908 · DOI:10.1016/j.esxm.2020.100298 Abstract only.
Inspected location: Abstract: methods and results
Study context and inspection record
FDA: Certain bulk drug substances for compounding that may present significant safety risks
US Food and Drug Administration. FDA web page. The footer states "Content current as of: 04/22/2026" (22 April 2026), independently verified on 2026-09-09 by two separate fetch methods. The ibutamoren mesylate row's own dated actions remain the applicable dates for that row's content. 2026-04-22. Regulatory document.
Inspected location: Ibutamoren mesylate row of the 503A/503B category-2 bulk-substances table: congestive-heart-failure safety-risk description and the row's own dated entries (503A added September 29, 2023; 503B added December 29, 2022). Also inspected for this batch: the category-2 table row for kisspeptin-10, and the withdrawn-nomination rows for BPC-157, cathelicidin LL-37, emideltide (DSIP), epitalon, GHK-Cu, melanotan II, MOTs-C, selank acetate (TP-7), semax (heptapeptide) and thymosin alpha-1; and the earlier named GHRP-6, PEG-MGF, GHK-Cu and GHRP-2 rows
Study context and inspection record
Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report.
Bonchev A. Life (Basel). 2026 Feb 3;16(2):265. DOI 10.3390/life16020265. 2026-02-03. PMID:41752902 · DOI:10.3390/life16020265 Abstract only.
Inspected location: Abstract: case description and three-month follow-up course
Study context and inspection record
Melanotan II: a possible cause of renal infarction: review of the literature and case report.
Peters B, Hadimeri H, Wahlberg R, Afghahi H. CEN Case Rep. 2020 May;9(2):159-161. Published online 2020-01-18. DOI 10.1007/s13730-020-00447-z. 2020-01-18. PMID:31953620 · DOI:10.1007/s13730-020-00447-z Abstract only.
Inspected location: Abstract: case description and discussion of possible mechanism
Study context and inspection record

Source inspection and clinical review are separate. An abstract check is not a full-text review. The records above identify what was actually inspected and do not certify the complete literature.

Recorded verification attempts

peptide-pmid-33460908: Abstract: methods and results

View this compound in the research library →

Related records in this class

Grouped under Peptides for navigation only. Shared class membership does not make findings, formulations or evidence interchangeable between records.